Summary of Study ST001619

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001038. The data can be accessed directly via it's Project DOI: 10.21228/M8HX30 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Show all samples  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001619
Study TitleMetabolomics Analysis: Opioid Addiction Project (Golestan Cohort Study) - NMR (part-II)
Study TypeUntargeted NMR Metabolomics Analysis
Study SummaryDrug addiction is a major threat to the public health in the US and many other countries. Opioid abuse is associated with increased risks for cancer, psychological complications, heart and lung disease, and infections of the liver and blood. Because metabolites are intrinsically involved in multiple metabolic pathways in vivo, the relative quantification of metabolites in body fluids (for example urine) can provide a profile of the metabolic state of an organism. Metabolomics is a powerful technique for revealing the impact of exposure on the overall biochemistry of an individual or system. Opioids can modify the output of urinary metabolites through many integrated neural and hormonal mechanisms within the periphery, central nervous system, and kidneys. Opioids modulate the expression of genes involved in neuroplasticity through epigenetic and possibly RNA modifications, ultimately change the intracellular signaling cascades and dysfunction, and cause long-lasting changes in metabolome. The objective of this study is to identify how opium impacts metabolic pathways to provide markers of abuse, long-term opium addiction, the addiction molecular pathway, and unknown metabolites that are important to differentiation of the study phenotypes. To reach these goals in the present study, the urine specimens of opium abusers and non-users as controls was profiled using an untargeted nuclear magnetic resonance spectroscopy (NMR) metabolomics platform at University of North Carolina at Chapel Hill. The Golestan Cohort Study is conducted in Northeast of Iran to primarily study the risk factors for upper gastrointestinal cancers in this high-risk region, in which about 50,000 volunteers were analyzed for opium users and their mortality. More than 8,000 of participants (17%) age 40-75 reported opium use with a mean duration of 12.7 years. Opium was either smoked or orally consumed. The participants were selected from the cohort stratified by opium use patterns and tobacco use.
Institute
University of North Carolina at Chapel Hill
DepartmentNutrition
LaboratoryUNC-NRI Sumner Lab
Last NameSumner
First NameSusan
Address500 Laureate Way, Kannapolis, NC, 28081, USA
Emailsusan_sumner@unc.edu
Phone919-622-4456
Submit Date2020-12-01
Num Groups2
Total Subjects298
Raw Data AvailableYes
Raw Data File Type(s)fid
Analysis Type DetailNMR
Release Date2022-05-02
Release Version1
Susan Sumner Susan Sumner
https://dx.doi.org/10.21228/M8HX30
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001038
Project DOI:doi: 10.21228/M8HX30
Project Title:Metabolomics Analysis: Opioid Addiction Project
Project Summary:Drug addiction is a major threat to the public health in the US and many other countries. Opioid abuse is associated with increased risks for cancer, psychological complications, heart and lung disease, and infections of the liver and blood. Because metabolites are intrinsically involved in multiple metabolic pathways in vivo, the relative quantification of metabolites in body fluids (for example urine) can provide a profile of the metabolic state of an organism. Metabolomics is a powerful technique for revealing the impact of exposure on the overall biochemistry of an individual or system. Opioids can modify the output of urinary metabolites through many integrated neural and hormonal mechanisms within the periphery, central nervous system, and kidneys. Opioids modulate the expression of genes involved in neuroplasticity through epigenetic and possibly RNA modifications, ultimately change the intracellular signaling cascades and dysfunction, and cause long-lasting changes in metabolome. The objective of this study is to identify how opium impacts metabolic pathways to provide markers of abuse, long-term opium addiction, the addiction molecular pathway, and unknown metabolites that are important to differentiation of the study phenotypes. To reach these goals in the present study, the urine specimens of opium abusers and non-users as controls was profiled using an untargeted nuclear magnetic resonance spectroscopy (NMR) metabolomics, and a quantitative targeted liquid chromatography mass spectrometric (LC-MS/MS) at University of North Carolina at Chapel Hill. The Golestan Cohort Study is conducted in Northeast of Iran to primarily study the risk factors for upper gastrointestinal cancers in this high-risk region, in which about 50,000 volunteers were analyzed for opium users and their mortality. More than 8,000 of participants (17%) age 40-75 reported opium use with a mean duration of 12.7 years. Opium was either smoked or orally consumed. The participants were selected from the cohort stratified by opium use patterns and tobacco use.
Institute:University of North Carolina at Chapel Hill
Laboratory:UNC-NRI Sumner Lab
Last Name:Sumner
First Name:Susan
Address:500 Laureate Way, Kannapolis, NC, 28081, USA
Email:susan_sumner@unc.edu
Phone:919-622-4456
Publications:1. Untargeted Metabolomics: Biochemical Perturbations in Golestan Cohort Study Opium Users Inform Intervention Strategies: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783045/
2. Metabolomics reveals biomarkers of opioid use disorder: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862627/

Subject:

Subject ID:SU001696
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Age Or Age Range:40-75
Gender:Male and female

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Phenotype
SA137574U_130Non-Opium User
SA137575U_13Non-Opium User
SA137576U_203Non-Opium User
SA137577U_131Non-Opium User
SA137578U_318Non-Opium User
SA137579U_132Non-Opium User
SA137580U_314Non-Opium User
SA137581U_138Non-Opium User
SA137582U_316Non-Opium User
SA137583U_204Non-Opium User
SA137584U_324Non-Opium User
SA137585U_43Non-Opium User
SA137586U_113Non-Opium User
SA137587U_282Non-Opium User
SA137588U_211Non-Opium User
SA137589U_210Non-Opium User
SA137590U_325Non-Opium User
SA137591U_285Non-Opium User
SA137592U_21Non-Opium User
SA137593U_14Non-Opium User
SA137594U_140Non-Opium User
SA137595U_17Non-Opium User
SA137596U_156Non-Opium User
SA137597U_309Non-Opium User
SA137598U_16Non-Opium User
SA137599U_169Non-Opium User
SA137600U_167Non-Opium User
SA137601U_166Non-Opium User
SA137602U_165Non-Opium User
SA137603U_153Non-Opium User
SA137604U_152Non-Opium User
SA137605U_145Non-Opium User
SA137606U_51Non-Opium User
SA137607U_175Non-Opium User
SA137608U_146Non-Opium User
SA137609U_147Non-Opium User
SA137610U_151Non-Opium User
SA137611U_310Non-Opium User
SA137612U_311Non-Opium User
SA137613U_304Non-Opium User
SA137614U_106Non-Opium User
SA137615U_84Non-Opium User
SA137616U_85Non-Opium User
SA137617U_86Non-Opium User
SA137618U_87Non-Opium User
SA137619U_83Non-Opium User
SA137620U_295Non-Opium User
SA137621U_8Non-Opium User
SA137622U_80Non-Opium User
SA137623U_235Non-Opium User
SA137624U_88Non-Opium User
SA137625U_89Non-Opium User
SA137626U_94Non-Opium User
SA137627U_268Non-Opium User
SA137628U_45Non-Opium User
SA137629U_93Non-Opium User
SA137630U_257Non-Opium User
SA137631U_239Non-Opium User
SA137632U_25Non-Opium User
SA137633U_296Non-Opium User
SA137634U_234Non-Opium User
SA137635U_71Non-Opium User
SA137636U_278Non-Opium User
SA137637U_293Non-Opium User
SA137638U_220Non-Opium User
SA137639U_279Non-Opium User
SA137640U_10Non-Opium User
SA137641U_168Non-Opium User
SA137642U_103Non-Opium User
SA137643U_101Non-Opium User
SA137644U_57Non-Opium User
SA137645U_39Non-Opium User
SA137646U_64Non-Opium User
SA137647U_273Non-Opium User
SA137648U_230Non-Opium User
SA137649U_228Non-Opium User
SA137650U_62Non-Opium User
SA137651U_221Non-Opium User
SA137652U_217Non-Opium User
SA137653U_59Non-Opium User
SA137654U_429Opium User
SA137655U_436Opium User
SA137656U_442Opium User
SA137657U_445Opium User
SA137658U_447Opium User
SA137659U_441Opium User
SA137660U_44Opium User
SA137661U_431Opium User
SA137662U_432Opium User
SA137663U_428Opium User
SA137664U_430Opium User
SA137665U_411Opium User
SA137666U_384Opium User
SA137667U_380Opium User
SA137668U_38Opium User
SA137669U_387Opium User
SA137670U_388Opium User
SA137671U_397Opium User
SA137672U_396Opium User
SA137673U_391Opium User
Showing page 1 of 4     Results:    1  2  3  4  Next     Showing results 1 to 100 of 334

Collection:

Collection ID:CO001689
Collection Summary:Non-fasted urine samples
Sample Type:Urine
Storage Conditions:-80℃

Treatment:

Treatment ID:TR001709
Treatment Summary:NA

Sample Preparation:

Sampleprep ID:SP001702
Sampleprep Summary:Aliquots of each de-identified sample were shipped to the NIH ERCMRC on dry ice and immediately stored at -80 °C after being logged in for metabolomics analysis. A total of 298 study urine samples were thawed at 4°C overnight. Aliquots of 400 µL of study samples were transferred to 2.0mL pre-labeled LoBind Eppendorf tubes. Aliquots of 400 µL of analytical quality control (QC) external pooled urine samples were also transferred to 2.0mL pre-labeled LoBind Eppendorf tubes. All samples were mixed with 300uL of NMR Master Mix solution containing Chenomx ISTD: DSS-d6 and Phosphate Buffer at 7.4 pH in D2O. The tubes were vortexed for 5 min on a multi-tube vortexer and centrifuged at 16,000 rcf for 10 min. A 600uL aliquot of supernatants were transferred into a pre-labeled 5mm 4 NMR tubes for data acquisition on a 700 MHz spectrometer.
Processing Storage Conditions:On ice
Extract Storage:Described in summary

Analysis:

Analysis ID:AN002654
Laboratory Name:ERCMRC
Analysis Type:NMR
Acquisition Date:March 14 to 20, 2018
Software Version:TopSpin 3.5
Operator Name:Kevin Knagge
Detector Type:NMR
Data Format:fid, 1r
Rt Units:No RT data
Units:ppm

NMR:

NMR ID:NM000190
Analysis ID:AN002654
Instrument Name:Avance III 700 MHz NMR Spectrometer
Instrument Type:FT-NMR
NMR Experiment Type:1D-1H
Field Frequency Lock:3015 Hz, D2O
Standard Concentration:0.5 mM
Spectrometer Frequency:700 MHz
NMR Probe:CP QCI/HPCN
NMR Solvent:90% H2O, 10% D2O
NMR Tube Size:5 mm
Shimming Method:topshim
Pulse Sequence:noesygppr1d
Water Suppression:pre-saturation
Pulse Width:14 microseconds
Power Level:12.3 Watts
Receiver Gain:36
Offset Frequency:3289.61 Hz
Presaturation Power Level:0.0000964 Watts
Chemical Shift Ref Cpd:DSS
Temperature:25 C
Number Of Scans:32
Dummy Scans:4
Acquisition Time:3.9 seconds
Relaxation Delay:2 seconds
Spectral Width:12 ppm
Num Data Points Acquired:65536
Real Data Points:32768
Line Broadening:0.5 Hz
Zero Filling:none
Apodization:Lorentzian
Baseline Correction Method:Polynomial
Chemical Shift Ref Std:DSS
Binned Increment:0.04ppm
Binned Data Excluded Range:4.69-4.90ppm (water), 5.50-6.00ppm (urea)
  logo